Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser, Nada Alachkar

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)128-130
Number of pages3
JournalNature Clinical Practice Nephrology
Issue number3
StatePublished - Mar 2014
Externally publishedYes

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Proteinuria: abate or applaud abatacept in proteinuric kidney disease?'. Together they form a unique fingerprint.

Cite this